Revere Pharmaceuticals
Dr. Levine is a medical oncologist and practiced clinical oncology for 30 years. He was managing partner of Connecticut Oncology and Hematology, LLC. He has served as a member of the clinical faculty in the Division of Oncology, Stanford University and Yale Medical School.
Dr. Levine was Chief Medical Officer of Egenix and Bantam Pharmaceutical, companies focused on development of small molecule therapeutics for cancer patients; and Chief Medical Officer of OncoPlex Diagnostics, a personalized medicine oncology molecular diagnostics company. He was a founding member and Executive VP of Oncology Partners, a consulting firm for development stage oncology companies.
This person is not in any offices
Revere Pharmaceuticals
Revere Pharmaceuticals is a Boston-based startup leading the way in the development of new cancer treatments targeting Rac1 GTPase, an important target in the progression of different cancers. R-ketorolac, their lead candidate, is a first-in-class Rac1 inhibitor that shows both clinical and non-clinical evidence of efficacy in ovarian cancer.